Air Pollution: Strategies for Personalized Intervention to Reduce Exposure

Air Pollution Clinical Trial

— ASPIRE  

Official title:

ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03744871
• Other study ID #: 03-18-20
• Secondary ID: R01ES019616
• Status: Completed
• Phase: N/A
• Start date: March 22, 2019
• Est. completion date: July 31, 2023

Study information

• Verified date: December 2023
• Source: University Hospitals Cleveland Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Fine particulate matter < 2.5 microns (PM2.5) air pollution is a leading global risk factor for cardiovascular morbidity and mortality. PM2.5 presents a serious ongoing public health threat to patients living in highly-polluted countries (ex: China, India) where air quality is projected to remain extremely poor (far exceeding World Health Organization Air Quality Guidelines) for the foreseeable future. This study reviews the benefits of personal level intervention (wearing N95 respirator) over long term, to prevent clinical events among patients with cardiovascular disease.

Description:

CLEANAIR-ACS will be an investigation within ASPIRE, that will test the ability of personal-level intervention (N95 respirators) to improve validated surrogate markers of cardio-metabolic health in patients with a recent Acute Coronary Syndrome (ACS). Patients with ACS are a vulnerable patient population with vulnerability and at risk for future cardiovascular events. This vanguard phase study in Beijing involving patients exposed to high levels of air pollution who have recently sustained an ACS event, is necessary to obtain feasibility data and gather a battery of information allowing for the appropriate design of a larger clinical outcome trial. What is more, positive results would provide critically-important information demonstrating for the first time that it is feasible to "prescribe" the use of these personal protection devices to cardiac patients, and that their usage is capable of translating into demonstrable health benefits (i.e., improved BP and insulin sensitivity) over the long-term.

The study hypothesis is that long-term personal-level interventions to reduce exposure to PM2.5 can be feasibly performed for 1-year post-acute coronary syndrome (ACS) and will result in significant improvements in validated surrogate cardiometabolic endpoints predictive of morbidity/mortality.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 31, 2023
• Est. primary completion date: July 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female >18, able to provide informed consent and willingness to complete the study protocol and measurement procedures, AND

2. Non-smoker of any type (cigarette, cigar, marijuana) during past six months (100% abstinence per self-report) and living in a non-smoking household (no person living in the household smoking at home) with confirmation of non-smoking status by urinary cotinine levels.

AND 3. A diagnosis of myocardial infarction or unstable angina 7-90 days prior to signed informed consent

Exclusion Criteria:

1. Inability for mental or physical reasons to understand and comply with the informed consent process and/or the study protocol procedures including wearing face mask (i.e: advanced COPD/lung disease requiring use of frequent inhalational or nebulizer treatments) per investigator discretion.

2. Obesity with arm circumference >18 inches preventing accurate BP determination during ABPM monitoring

3. Significant hemodynamically unstable CV disorder including uncompensated heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease and severe hypertension. (as further described in Appendix B) at screening

4. ESRD on dialysis or patients that have received dialysis within 14 days prior to screening

5. Subject has a history of infection with human immunodeficiency virus

6. Subject has a history of alcohol or substance abuse within the 6 months prior to the screening

7. Advanced COPD on home oxygen

8. Past diagnosis of sleep apnea either untreated or treated with CPAP

9. History of malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and localized Prostate cancer) AND/OR any severe, life-threatening disease AND/OR history of drug abuse within the last 2 years

10. Regular use of any over-the-counter drug, recreational medication including stimulants (amphetamines) and/or complimentary or herbal therapy that might impact study outcomes including BP and insulin sensitivity per investigator discretion.

11. In women of childbearing age: pregnancy, non-use of approved method of birth control, intent to get pregnant during the study period

12. Patients with passive home cigarette smoking

13. Other medical or psychosocial conditions or life circumstances that may put the subject at increased risk of participation or jeopardizes the scientific integrity of the study, as determined by the investigators

-

Related Conditions & MeSH terms

• Air Pollution

Intervention

Other:
• N95 Respirator
SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).

Locations

Country	Name	City	State
China	Peking University	Beijing
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio

Sponsors (3)

Lead Sponsor	Collaborator
University Hospitals Cleveland Medical Center	Peking University, University of Michigan

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Pressure	Use Omron 907xl for clinic BP Measures, with 3 repeated measurements after 5 minutes after clinicians leave room (patient unattended). Averages of the 3 BP Recordings will be obtained	12 months
Secondary	PWV and pulse wave analysis	To be measured at clinic visits, with Omron used in JI Study	12 months
Secondary	BP/HRV Monitoring	24 hour ambulatory HRV/BP will be placed when clinic BP is complete as the first clinic measure. The monitoring systems have been used in JI study previously	12 months